The severity of a person's psoriasis before and during treatment should be assessed by considering the redness, thickness and scaliness of the plaques, the area of the body involved, and how the condition...
Psoriasis is a common, chronic inflammatory skin disease which typically follows a relapsing and remitting course, and is associated with joint disease in approximately 25% of patients.
To provide the dermatologist a guide focuses specifically on the diagnosis and management of the diseases most often found in patients with psoriasis.
A readily accessible summary for PCPs of the current evidence base and practical guidance on best practice in a number of psoriasis scenarios, from the UK's National Institute for Health and Care Excellence (NICE).
This document contains a single pathway diagram and uses numbering to link the boxes to the associated recommendations.
Evidence-based recommendations on adalimumab (Humira) for treating active moderate to severe hidradenitis suppurativa in adults whose disease has not responded to conventional systemic therapy.
Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics.
Since the publication of the 2009 Canadian Guidelines for the Management of Plaque Psoriasis, significant advances have been made in determining the role of T cells in inflammatory and autoimmune diseases.
The relationship between psoriasis and associated diseases has drawn particular interest in recent years. To provide appropriate management of psoriasis from an early stage, it is necessary to include prompt diagnosis of concomitant disease...
In recognition of the impact of psoriasis on patients the World Health Assembly (WHA) in May 2014 supported including psoriasis into the group of non-communicable diseases.